Attached files
| file | filename |
|---|---|
| EX-1.1 - EX-1.1 - STEMLINE THERAPEUTICS INC | a2211609zex-1_1.htm |
| EX-3.7 - EX-3.7 - STEMLINE THERAPEUTICS INC | a2211609zex-3_7.htm |
| EX-4.2 - EX-4.2 - STEMLINE THERAPEUTICS INC | a2211609zex-4_2.htm |
| EX-5.1 - EX-5.1 - STEMLINE THERAPEUTICS INC | a2211609zex-5_1.htm |
| EX-10.27 - EX-10.27 - STEMLINE THERAPEUTICS INC | a2211609zex-10_27.htm |
| EX-10.26 - EX-10.26 - STEMLINE THERAPEUTICS INC | a2211609zex-10_26.htm |
| S-1/A - S-1/A - STEMLINE THERAPEUTICS INC | a2210473zs-1a.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated April 2, 2012 (except for the paragraph under the caption "Immaterial Reclassification of Research and Development Costs" within Note 2, as to which the date is May 21, 2012, and except for the paragraph under the caption "Common Stock Splits" within Note 12, as to which the date is November 14, 2012) in Amendment No. 6 to the registration statement (Form S-1 No. 333-180515) and related Prospectus of Stemline Therapeutics, Inc. dated November 14, 2012.
/s/ Ernst & Young LLP
MetroPark,
New Jersey
November 14, 2012
Consent of Independent Registered Public Accounting Firm